Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs

Translational Psychiatry

Volumn 6, Issue 1, 2016, Pages

  Dong, E ^a   Tueting, P ^a   Matrisciano, F ^a   Grayson, D R ^a   Guidotti, A ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETIC EPIGENESIS; MENTAL STRESS; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLOZAPINE; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FEMALE; MICE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REAL-TIME POLYMERASE CHAIN REACTION; STRESS, PSYCHOLOGICAL;

EID: 84994878601     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2015.191     Document Type: Article

References (51)

1. Matrisciano F, Tueting P, Dalal I, Kadriu B, Grayson DR, Davis JM et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 2013; 68: 184–194.
2. Dong E, Dzitoyeva S, Matrisciano F, Tueting P, Grayson DR, Guidotti A. BDNF epigenetic modifications associated with schizophrenia-like phenotype induced by prenatal stress in mice. Biol Psychiatry 2015; 77: 589–596.
3. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660–669.
4. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009; 35: 528–548.
5. Khashan AS, Abel KM, McNamee R, Pedersen MG, Webb RT, Baker PN et al. Higher risk of offspring for schizophrenia following antenatal maternal exposure to severe adverse life events. Arch Gen Psychiatry 2008; 65: 146–152.
6. Markham JA, Koenig JI. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology 2011; 214: 89–106.
7. Giovanoli S, Meyer U. Response to comment on 'Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice". Science 2013; 340: 811.
8. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167: 261–280.
9. Van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203–212.
10. Zhang TY, Labonte B, Wen XL, Turecki G, Meaney MJ. Epigenetic mechanisms for the early environmental regulation of hippocampal glucocorticoid receptor gene expression in rodents and humans. Neuropsychopharmacology 2013; 38: 111–123.
11. Stevens HE, Su T, Yanagawa Y, Vaccarino FM. Prenatal stress delays inhibitory neuron progenitor migration in the developing neocortex. Psychoneur-oendocrinology 2013; 38: 509–521.
12. Fine R, Zhang J, Stevens HE. Prenatal stress and inhibitory neuron systems: implications for neuropsychiatric disorders. Mol Psychiatry 2014; 19: 641–651.
13. Grigoryan G, Segal M. Prenatal stress affects network properties of rat hippo-campal neurons. Biol Psychiatry 2013; 73: 1095–1102.
14. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312–324.
15. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psycho-pharmacology 2005; 180: 191–205.
16. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008; 82: 696–711.
17. Pidsley R, Viana J, Hannon E, Spiers HH, Troakes C, Al-Saraj S et al. Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schi-zophrenia. Genome Biol 2014; 15: 483.
18. Ruzicka WB, Subburaju S, Benes FM. Circuit-and diagnosis-specific DNA methy-lation changes at gamma-aminobutyric acid-related genes in postmortem human hippocampus in schizophrenia and bipolar disorder. JAMA Psychiatry 2015; 72: 541–551.
19. Grayson DR, Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 2013; 38: 38–66.
20. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234–242.
21. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bul 2008; 34: 944–961.
22. Dickerson DD, Overeem KA, Wolff AR, Williams JM, Abraham WC, Bilkey DK. Association of aberrant neural synchrony and altered GAD67 expression following exposure to maternal immune activation, a risk factor for schizophrenia. Transl Psychiatry 2014; 4: e418.
23. Matrisciano F, Tueting P, Maccari S, Nicoletti F, Guidotti A. Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology 2012; 37: 929–938.
24. Houston I, Peter CJ, Mitchell A, Straubhaar J, Rogaev E, Akbarian S. Epigenetics in the human brain. Neuropsychopharmacology 2013; 38: 183–197.
25. Guidotti A, Auta J, Chen Y, Davis JM, Dong E, Gavin DP et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 2011; 60: 1007–1016.
26. Ikegame T, Bundo M, Murata Y, Kasai K, Kato T, Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. JHumGenet2013; 58: 434–438.
27. Dong E, Ruzicka WB, Grayson DR, Guidotti A. DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients. Schizophr Res 2015; 167: 35–41.
28. Gavin DP, Sharma RP, Chase KA, Matrisciano F, Dong E, Guidotti A. Growth arrest and DNA-damage-inducible, beta (GADD45b)-mediated DNA demethylation in major psychosis. Neuropsychopharmacology 2012; 2: 531–542.
29. Dong E, Gavin D, Chen Y, Davis J. Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients. Transl Psychiatry 2012; 2: e159.
30. Guidotti A, Dong E, Tueting P, Grayson DR. Modeling the molecular epigenetic profile of psychosis in prenatally stressed mice. Prog Mol Biol Transl Sci 2014; 128: 89–101.
31. Ribeiro BM, do Carmo MR, Freire RS, Rocha NF, Borella VC, de Menezes AT et al. Evidence for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: reversal by clozapine. Schizophr Res 2013; 151: 12–19.
32. Meyer U, Knuesel I, Nyffeler M, Feldon J. Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. Psychopharmacology 2010; 208: 531–543.
33. Basil P, Li Q, Dempster EL, Mill J, Sham PC, Wong CCY et al. Prenatal maternal immune activation causes epigenetic differences in adolescent mouse brain. Transl Psychiatry 2014; 4: e434.
34. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358–403.
35. Meltzer HY. Serotonergic mechanisms as targets for existing and novel anti-psychotics. Handb Exp Pharmacol 2012; 212: 87–124.
36. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med 2013; 64: 393–406.
37. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008; 172: 177–197.
38. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci USA 2008; 105: 13614–13619.
39. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remo-deling. Trends Pharmacol Sci 2009; 30: 55–60.
40. Montalvo-Ortiz JL, Keegan J, Gallardo C, Gerst N, Tetsuka K, Tucker C et al. HDAC inhibitors restore the capacity of aged mice to respond to haloperidol through modulation of histone acetylation. Neuropsychopharmacology 2014; 39: 1469–1478.
41. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
42. Jin SG, Wu X, Li AX, Pfeifer GP. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res 2011; 39: 5015–5024.
43. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res 2004; 32: 4100–4108.
44. Wen L, Li X, Yan L, Tan Y, Li R, Zhao Y et al. Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. Genome Biol 2014; 15: R49.
45. Detich N, Bovenzi V, Szyf M. Valproate induces replication independent active DNA demethylation. J Biol Chem 2003; 278: 27586–27592.
46. Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neuroscience 2012; 15: 1243–1254.
47. Long HK, Blackledge NP, Klose RJ. ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection. Biochem Soc Trans 2013; 41: 727–740.
48. Day JJ, Kennedy AJ, Sweatt JD. DNA methylation and its implications and accessibility for neuropsychiatric therapeutics. Annu Rev Pharmacol Toxicol 2015; 55: 591–611.
49. Wassef AA, Dott SG, Harris A, Brown A, O`Boyle M, Meyer WJ et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000; 20: 357–361.
50. Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2008; 34: 1030–1038.
51. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci 2007; 27: 11254–11262.